Cardiovascular therapy comprises of Anti-hypertensives , anticoagulants , anti-arrhythmic , Antithrombotics and Antidyslipidemics . Global cardiovascular market had a sale of $ 170bn in 2010 and is expected to have a positive growth in the forecast period . With a share of 40 % of the total market , the US continued to be the market leader in this segment . Although there has been a decline in the sales of cardiovascular therapy market due to saturation of key drug categories and an increased generic presence , the US witnessed a steady growth in the market since 2009 and is expected to continue the same trend .
Antihypertensives remained the largest drug class in the past few years with global sales of over $ 37.6bn and an overall market share of over 22 %. Angiotensin receptor blockers ( ARBs ) is expected to remain the most prescribed therapeutic class within antihypertensives driven by key brands such as Cozaar , Diovan , and Avapro . Novartis ’ s Diovan is the market leader with $ 3.6bn in sales and the second largest being Benicar with sales of $ 2.9bn . The anticoagulants segment is expected to witness significant activity over the forecast period owing to introduction of new drugs such as BoehringerPradaxa / Rendix , Ingelheim ' s , Bayer-Schering / J & J ' s , BMS / Pfizer ' s apixaban , Xarelto and Eli Lilly / Daiichi ' s Effient which are subjected to intensive R & D activities . Since most of the factor Xa inhibitors are in oral form , they are expected to cater to a wider market .
Browse Full Research Report @ https :// www . millioninsights . com / industry-reports / cardiovascular-therapy-market
Crestor is expected to witness a steady growth in the market owing to positive trial results that has the capability to strengthen its market position . The positive trial data is likely to result in higher number of recommendations for cholesterol treatment and capture more number of patients with cardiovascular disorders GlaxoSmithKline ' s ( GSK ) is expected to have the highest growth among leading players owing to the acquisition of Reliant Pharma . Addition of new drugs such as Lovaza in GSKs portfolio is a key factor that can drive the growth in this segment In 2010 , Antithrombotics recorded a sale of over $ 18.7bn and a market share of over 11 %. Antithrombitics are forecasted to witness a strong growth in the next seven years owing to increase in the commercialization of recently approved products such as Xarelto , Pradaxa and launch of Pfizer / BMS ’ s apixabanBetter bleeding profile and superior effectiveness of Brilinta ( ticagrelor ) over Plavix make it major antithrombotic drug that could be a key player in acute coronary syndrome ( ACS ).
A large segment of atherosclerosis patients who do not respond to Plavix can be administered by Brilinta which has a potential therapeutic advantage in atherosclerosis Moreover , its use could be initially confined to acute coronary syndrome ( ACS ) with no patient monitoring anticipated for postmarketing surveillanceor respiratory or cardiac function requirements . The anti-arrhythmic market is expected to remain a small opportunity as this drug therapy has substantial limitations . New therapeutic standards and benchmarks are expected to be set by Multaq from Sanofi-Aventis owing to its first-line treatment of chronic atrial fibrillation .